These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27366711)

  • 1. Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India.
    Vikrant S; Parashar A
    Indian J Endocrinol Metab; 2016; 20(4):460-7. PubMed ID: 27366711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study.
    Ghosh B; Brojen T; Banerjee S; Singh N; Singh S; Sharma OP; Prakash J
    Indian J Nephrol; 2012 Jul; 22(4):285-91. PubMed ID: 23162273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of chronic kidney disease-mineral bone disorders in newly detected advanced renal failure patients: A Hospital-based cross-sectional study.
    Etta PK; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2017; 28(4):874-885. PubMed ID: 28748891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posterior urethral valves: Metabolic consequences in a cohort of patients.
    Sarhan O; Nakshabandi Z; Alghanbar M; Alotay A; Sherif I; Whitehead C; El-Husseini A
    J Pediatr Urol; 2015 Aug; 11(4):216.e1-6. PubMed ID: 26096436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THE PREVALENCE OF BIOCHEMICAL ABNORMALITIES OF CHRONIC KIDNEY DISEASE. MINERAL AND BONE DISORDERS IN UNTREATED NON-DIALYSIS PATIENTS - A MULTICENTER STUDY.
    Căpuşă C; Chirculescu B; Vladu I; Viaşu L; Lipan M; Moţa E; Mircescu G
    Acta Endocrinol (Buchar); 2016; 12(3):282-290. PubMed ID: 31149102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.
    Ambrus C; Molnar MZ; Czira ME; Rosivall L; Kiss I; Remport A; Szathmari M; Mucsi I
    Int Urol Nephrol; 2009 Dec; 41(4):1029-38. PubMed ID: 19701690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.
    Liabeuf S; McCullough K; Young EW; Pisoni R; Zee J; Reichel H; Pecoits-Filho R; Port FK; Stengel B; Csomor PA; Metzger M; Robinson B; Massy ZA
    Bone; 2019 Dec; 129():115058. PubMed ID: 31493530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive assessment of bone health in Indian patients with chronic kidney disease.
    Jabbar Z; Aggarwal PK; Chandel N; Khandelwal N; Kohli HS; Sakhuja V; Jha V
    Indian J Nephrol; 2013 May; 23(3):161-7. PubMed ID: 23814412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?
    Weissheimer R; Bucharles SGE; Truyts CAM; Jorgetti V; Figueiredo AE; Barrett P; Olandoski M; Pecoits-Filho R; Moraes TP
    J Bras Nefrol; 2021; 43(2):173-181. PubMed ID: 33538758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4.
    Stavroulopoulos A; Porter CJ; Roe SD; Hosking DJ; Cassidy MJ
    Nephrology (Carlton); 2008 Feb; 13(1):63-7. PubMed ID: 18199106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral and bone disorder biomarkers and inflammation indexes in patients with end stage renal disease.
    Zhang L; Yu Q; Chen X; Zhang M; He Y; Ji Z; Chen R; Zhang J; Zhang H; Shi G; Huang J
    Ann Palliat Med; 2020 Nov; 9(6):3938-3946. PubMed ID: 33302656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To what extent can we achieve mineral bone metabolism treatment targets suggested by the KDIGO guidelines among chronic kidney disease stage 3 - 5 non-dialysis patients?
    Dincer MT; Ozcan SG; Alagoz S; Karaca C; Gulcicek SH; Trabulus S; Pekpak M; Seyahi N
    Clin Nephrol; 2022 Nov; 98(5):239-246. PubMed ID: 35979902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Prevalence and Severity of Dysregulated Bone Mineral Homeostasis in Nondialyzed Chronic Kidney Disease Patients.
    Patel DD; Vachhani U; Rajput A; Raghavani P; Parchwani DN; Dholariya S
    J Lab Physicians; 2022 Jun; 14(2):144-150. PubMed ID: 35982879
    [No Abstract]   [Full Text] [Related]  

  • 17. Mineral bone disorder in children with chronic kidney disease: Data from the KNOW-Ped CKD (Korean cohort study for outcome in patients with pediatric chronic kidney disease) study.
    Jung J; Lee KH; Park E; Park YS; Kang HG; Ahn YH; Ha IS; Kim SH; Cho H; Han KH; Cho MH; Choi HJ; Lee JH; Shin JI
    Front Pediatr; 2023; 11():994979. PubMed ID: 36873652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
    Kumar N; Lindberg J; David K; Morris J; Menoyo J
    Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of incident chronic kidney disease related-mineral bone disorders in chronic kidney disease Stage 4 and 5: A hospital based cross-sectional survey.
    Valson AT; Sundaram M; David VG; Deborah MN; Varughese S; Basu G; Mohapatra A; Alexander S; Jose J; Roshan J; Simon B; Rebekah G; Tamilarasi V; Jacob CK
    Indian J Nephrol; 2014 Mar; 24(2):97-107. PubMed ID: 24701042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.